



October 19, 2022

**VIA EDGAR**

Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549-7010  
USA

**Re: Aptose Biosciences Inc.  
Registration Statement on Form S-3  
Filed October 11, 2022  
File No. 333- 267801**

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aptose Biosciences Inc. (the "Company") hereby respectfully requests that the Securities and Exchange Commission (the "Commission") accelerate the effective date of the above-referenced Registration Statement (the "Registration Statement") to October 21, 2022 at 5:00 p.m. (Eastern) or as soon thereafter as is practicable.

The Company also requests the Commission confirm the effective date and time of the Registration Statement in writing.

**APTOSE BIOSCIENCES INC.**

By: /s/ Fletcher Payne  
Name: Fletcher Payne  
Title: Senior Vice President & Chief Financial Officer

